| Deciphera Pharmaceuticals Inc (DCPH) | |||
|---|---|---|---|
| 14.65 0.47 (3.31%) | 04-26 16:00 | ||
| Open: | 14.21 | Pre. Close: | 14.18 |
| High: | 14.84 | Low: | 14.09 |
| Volume: | 317,395 | Market Cap: | 1,204(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 17.92 One year: 18.89 |
| Support: | Support1: 14.00 Support2: 11.65 |
| Resistance: | Resistance1: 15.34 Resistance2: 16.17 |
| Pivot: | 14.86  |
| Moving Averages: | MA(5): 14.54 MA(20): 14.98 MA(100): 15.31 MA(250): 14.07 |
| MACD: | MACD(12,26): -0.29 Signal(12,26,9): -0.25 |
| %K %D: | %K(14,3): 26.08 %D(3): 28.17 |
| RSI: | RSI(14): 44.93 |
| 52-Week: | High: 17.73 Low: 9.9 Change(%): 3.1 |
| Average Vol(K): | 3-Month: 515 10-Days: 427 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 14.861 - 14.944 | 14.944 - 15.021 |
| Low: | 13.875 - 13.982 | 13.982 - 14.079 |
| Close: | 14.492 - 14.65 | 14.65 - 14.795 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DCPH ] has closed above bottom band by 37.9%. Bollinger Bands are 28.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - Specialty & Generic | |
| Shares Out. (M) | 80.80 |
| Shares Float (M) | 41.98 |
| % Held by Insiders | 30.49 |
| % Held by Institutions | 73.54 |
| Shares Short (K) | 6060 |
| Shares Short Prior Month (K) | 5510 |
| Stock Financials | |
|---|---|
| EPS | -2.290 |
| Book Value (p.s.) | 4.360 |
| Profit Margin | -119.34 |
| Operating Margin | -106.10 |
| Return on Assets (ttm) | -28.4 |
| Return on Equity (ttm) | -56.3 |
| Qtrly Rev. Growth | 32.9 |
| Gross Profit (p.s.) | |
| Sales Per Share | 2.022 |
| EBITDA (p.s.) | -2.585 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -146.70 |
| Levered Free Cash Flow (M) | -72.79 |
| Stock Valuation | |
|---|---|
| PE Ratio | -6.40 |
| PEG Ratio | -0.31 |
| Price to Book value | 3.36 |
| Price to Sales | 7.25 |
| Price to Cash Flow | -8.07 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
